BUGATTI, SERENA
 Distribuzione geografica
Continente #
NA - Nord America 1.749
EU - Europa 1.173
AS - Asia 682
OC - Oceania 3
SA - Sud America 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.614
Nazione #
US - Stati Uniti d'America 1.738
CN - Cina 637
IE - Irlanda 456
FI - Finlandia 189
DE - Germania 142
UA - Ucraina 129
IT - Italia 115
SE - Svezia 77
SG - Singapore 36
GB - Regno Unito 23
BE - Belgio 13
CA - Canada 11
FR - Francia 10
RU - Federazione Russa 9
CZ - Repubblica Ceca 6
IN - India 4
AU - Australia 2
BR - Brasile 2
EU - Europa 2
IL - Israele 2
ZM - Zambia 2
CL - Cile 1
ES - Italia 1
GR - Grecia 1
IR - Iran 1
KR - Corea 1
NL - Olanda 1
NZ - Nuova Zelanda 1
RO - Romania 1
TR - Turchia 1
Totale 3.614
Città #
Dublin 451
Chandler 415
Jacksonville 194
Nanjing 194
Boardman 122
Ashburn 118
Helsinki 103
Princeton 81
Lawrence 75
Wilmington 74
Nanchang 67
Ann Arbor 64
Beijing 62
New York 59
Shenyang 58
Medford 51
Hebei 50
Shanghai 50
Changsha 44
Jiaxing 36
Milan 28
Hangzhou 23
Singapore 21
Pavia 20
Tianjin 19
Munich 18
Piscataway 18
Woodbridge 18
Seattle 15
Brussels 13
Fairfield 11
Norwalk 11
Berlin 7
Washington 7
Brno 6
Toronto 6
Verona 6
Dallas 5
Los Angeles 5
Taizhou 5
Houston 4
Menlo Park 4
Sassari 4
Zhengzhou 4
Bollate 3
Falkenstein 3
Falls Church 3
Fort St. James 3
Kunming 3
Ningbo 3
Segrate 3
Sona 3
Tappahannock 3
Bad Sobernheim 2
Buffalo 2
Bulgorello 2
Busto Arsizio 2
Chicago 2
Des Moines 2
Florence 2
Frankfurt am Main 2
Fremont 2
Genoa 2
London 2
Monza 2
Nanaimo 2
Orange 2
Padova 2
Pune 2
Ramat Gan 2
Rozzano 2
San Francisco 2
Bolzano 1
Borås 1
Brivio 1
Buccinasco 1
Canberra 1
Changchun 1
Desio 1
Elk Grove Village 1
Fagnano Olona 1
Fuzhou 1
Gostar 1
Guangzhou 1
Gunzenhausen 1
Haikou 1
Hanover 1
Hyderabad 1
Lungavilla 1
Madrid 1
Messina 1
Mumbai 1
Novokuznetsk 1
Philadelphia 1
Portland 1
Rockville 1
San Diego 1
Santa Clara 1
Sarapul 1
Serramanna 1
Totale 2.739
Nome #
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. 89
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 82
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 80
B cells in rheumatoid arthritis. 77
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 72
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 71
Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography 69
B cells in rheumatoid arthritis. 67
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 66
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 63
Long term treatment of rheumatoid arthritis with rituximab. 62
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 60
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 60
Long term treatment of rheumatoid arthritis with rituximab 59
Nuovi aspetti patogenetici dell’artrite reumatoide 59
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 57
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 56
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 56
Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs 55
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 55
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 54
B cell autoimmunity and bone damage in rheumatoid arthritis 54
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 53
Subchondral Bone Marrow Inflammatory Involvement in Rheumatoid Arthritis: Lymphoid Neogenesis and In Situ Relationship with Subchondral Bone Marrow Osteoclasts 53
Synovial tissue heterogeneity and peripheral blood biomarkers 52
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment 52
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 52
The draining lymph node in rheumatoid arthritis: current concepts and research perspectives 51
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 51
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs 49
Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment? 49
Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? 49
Early treatment in early undifferentiated arthritis 48
Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases 46
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 46
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 45
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 44
Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. 44
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 44
Long-term safety of abatacept in patients with rheumatoid arthritis 43
The constitutive pattern of CCL21 production is maintained in inflammatory lesions with lymphoid neogenesis 43
In patients with early peripheral psoriatic arthritis baseline c-reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts/bdmards. A retrospective analysis 42
A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy 41
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 41
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. 40
Seronegative autoimmune diseases: A challenging diagnosis 39
Differences and similarities in rheumatology specialty training programmes across European countries 39
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 39
Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique 38
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. 38
Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter-Determining Validation Requirements 38
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target 38
Adult-onset Still's disease with elderly onset, results from a multicentre study 38
La linfoneogenesi 37
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. 36
The Clinical Value of Autoantibodies in Rheumatoid Arthritis. 36
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis 35
A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019 34
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium 33
Clinical Applications of Synovial Biopsy. 33
Established rheumatoid arthritis. The pathogenic aspects. 33
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 33
Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials 32
Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients 32
High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease 32
Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis 32
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 31
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 31
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 31
Insights Into the Concept of Rheumatoid Arthritis Flare 31
No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission 30
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib 30
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 30
Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study 29
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline 27
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 27
Rheumatology training experience across Europe: Analysis of core competences 25
Histopathology of the synovial tissue: Perspectives for biomarker development in chronic inflammatory arthritides. 25
Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective 25
Transient monoarthritis and psoriatic skin lesions following COVID-19 22
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 21
A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNFα 19
Correction to: Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts 19
Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study 17
Seronegative rheumatoid arthritis: one year in review 2023 16
Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis 16
Anti-neutrophil cytoplasmic antibodies (ANCA) 16
Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis? 16
Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis 15
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial 15
Tumor necrosis factor-α inhibitor-related autoimmune disorders 14
The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis 13
The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis 12
Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology 11
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 11
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia 8
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 8
Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 7
Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases 7
Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database 3
Totale 3.904
Categoria #
all - tutte 17.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.213


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020470 0 284 4 27 0 29 4 31 10 37 40 4
2020/2021283 28 21 10 25 0 31 8 51 16 45 37 11
2021/2022362 4 3 12 14 10 26 15 23 19 8 54 174
2022/20231.352 143 103 11 86 104 126 1 72 529 20 50 107
2023/2024626 46 182 22 30 53 149 23 34 11 12 31 33
2024/2025151 43 108 0 0 0 0 0 0 0 0 0 0
Totale 3.904